Difference between revisions of "Part:BBa K2457000"

Latest revision as of 03:24, 2 November 2017

araC + pBAD arabinose inducible promoter

Arabinose inducible promoter pBAD forward + araC regulatory reverse gene under control of pC promoter and tryptophan terminator sequence.

Figure 1: BBa_K2457000 Circuit.

Usage and Biology

Inductor: L-Arabinose

Repressor: Glucose

The BBa_K2457000 includes approximately 1298 nucleotides and is used to regulate transgene expression in Escherichia coli bacteria. This construction is composed by the araBAD (PBAD) promoter, a medium force promoter, the L-Arabinose operon, in 5’ → 3’ direction with a upstream native RBS, two regulatory sites: I1 and I2, and two operators sites AraO: O1 and O2. It is composed also by the promoter PC that transcribes the regulatory protein AraC gene, followed to tryptophan transcription terminator, in 3’ → 5’ (reverse) (KUHLMAN & COX, 2010).

The PC Promoter, which is adjacent to PBAD promoter, transcribes the AraC gene in the opposite direction. AraC regulates the promoter’s function. In L-Arabinose absence, AraC dimerizes and binds itself in O2 and I1 operators, making a DNA “loop” around 210bp and avoiding the CAP-cAMP binding. Then it connects to a binding site upstream to the I1 and I2 operators and RNA polymerase, that normally activate the transcription from PBAD and PC promoters (ENGLESBERG et al, 1965, YANOFSKY et al, 1981). In the presence of L-Arabinose, the pBAD expression is activated, meanwhile, the L-Arabinose induces very low levels of PBAD transcription.

The beginning of transcription by PBAD is only activated in L-Arabinose presence and low levels of glucose. L-Arabinose binds itself to AraC protein and the AraC N-terminal arm is released from its DNA binding domain through a “dimerization” mechanism. AraC changes its conformation and connects on I1 and I2 operators, allowing the CAP access to their binding site and it helps to recruit the RNA polymerase to the PBAD e PC promoters and, then, activates the gene transcription (GUZMAN et al, 1995).

Although the L-Arabinose quantity may vary accordingly your expression experiment, the suggested L-Arabinose quantity is between 0,00002% and 0,2%.

Assembly

The sequence was ordered as gBlocks from Integrated DNA Technologies and it was assembled by restriction enzyme site.

Figure 2: Eletrophoretic profile of restriction digestion of BBa_K2457000.

Characterization

BBa_K2457000 was used by Amazonas_Brazil team in two methods based on standard BioBricks modules for bacterial genome engineering mediated by CRISPR-Cas9 machinery: the CRISPeasys. The approaches constructed were 1) for non-homologous end joining (NHEJ) repair pathway, the CRISPeasy-out method (or crOUT), referring to knock-out and the 2) for homologous directed repair (HDR), the CRISPeasy-in method (or crIN), referring to knock-in.

Figure 3: CRISPeasy subdivisions.

1. CROUT (CRISPeasy-out method): Designed for knock-out strategy for bacterial genome editing based on CRISPR/Cas9

In order to characterize our genetic modules, It was transformed by electroporation E. coli K12 MG1655 with BBa_K2457006 (pBAD_Cas9_sgRNA). We took isolated colonies to pre-inoculate in 5mL of Luria-Bertani (LB), incubating overnight in a shaker at 37ºC. After that, we measured the Optical Density (OD) on spectrophotometer 600 nm aiming to standardize the cell ratio to 1 OD. All the samples were inoculated to 0.05 OD. Our experiment was performed in 96-well plates with 200µL of LB + 25µg/mL chloramphenicol, measuring the cell growth for over 8h in a range of conditions (see the layout plate below). We implemented Hidex Chameleon spectrophotometer to measure the OD and incubate the 96-well plates into shaker at 37°C. As a control, we employed MG1655 carrying two genetic circuits: BBa_K2457001 (Standardized Cas9 coding sequence without regulatory modules) AND BBa_K2457005 (Cas9 device without sgRNA).

Glucose 1% was applied as a repressor to understand the activation and deactivation of the Cas9 expression and was added in 50% of the samples. The L-Arabinose solution is used as the inductor of the AraC_pBAD regulatory module controlling the Cas9 expression and was added in 75% of the samples, on respective concentrations: 0,05%, 0,1% and 0,2%. It was added at 1, 2, 3 and 4 hours of cell growth.

Figure 4: CRISPeasy-out results.

Based on a range of experiments involving the knocking-out process, we could propose that in the glucose (repressor) absence AND in the arabinose presence (inductor), MG1655 transformed with the BBa_K2457006 vector, carrying the Cas9 device and constitutively expressing sgRNA, reported a meaningful lower growth in contrast with the samples without the regulatory module (BBa_K2457001) OR without the sgRNA (BBa_K2457005). And, in the glucose presence, repressing the Cas9 expression, all the samples displayed a similar growth performance. The samples which carried the sgRNA (i.e., directing the Cas9 sequence to lead the DSB into a specific point of the genome) presented a low cell viability, supporting the hypothesis that even occurring the Non-Homologous End Joining (NHEJ) cell repair, not all cells could recover themselves, leading to the cellular death. Thus, we founded our proof of concept on the well-characterized impact caused by the Cas9 activity into the cellular machinery AND cell growth.

2. CRIN (CRISPeasy-in method): Designed for knock-in strategy for bacterial genome editing based on CRISPR/Cas9

As the main key to this method, there is an AND logic gate composed of Cas9 coupled with RecA, which operates the Donor DNA insertion into E. coli genome through Direct Homology Repair (HDR). In this way, the arabinose AND IPTG (the inputs) activate the gene expression program encoding Cas9 and RecA. Then, there is the execution of their hardware's (physical parts, e.g. proteins) operation. As an output, Cas9 AND RecA activate the DNA insertion into the genome. In order to standardize a reliable datasheet of genome engineering efficiency, we tested a range of electrocompetent E. coli K12 MG1655 cells with different circuits: test A) carrying a non-pre-inducted Cas9 device + sgRNA (BBa_K2457006) plasmid; B) carrying a pre-inducted Cas9 AND RecA; C) carrying a pre-inducted RecA. The donor DNA was electroporated in all the tests.

Figure 5: CRISPeasy-in methodologies.

A) carrying a non-pre-inducted Cas9 device + sgRNA;

We transformed through electroporation E. coli K12 MG1655 carrying a non-pre-inducted pBAD_Cas9_sgRNA plasmid CamR+ (BBa_K2457006) with pRecA (AmpR+) and a linearized Donor DNA (BBa_K2457004). We screened over 94 transformants colonies, inoculating in 200µL of LB + 25µg/mL chloramphenicol + 100µg/mL ampicillin + 0.2% L-Arabinose + 1mM IPTG to activate the expression of RecA AND Cas9. We measured the initial OD (600nm) and initial fluorescence (exc. 340 nm em. 530 nm) on 96-wells plates applying the Hidex Chameleon V spectrofluorimeter. The process was repeated for each hour over 10 hours while the 96-wells plate kept growing on a shaker at 37ºC.

B) carrying a pre-inducted Cas9 + sgRNA AND RecA;

We transformed through electroporation E. coli K12 MG1655 carrying a pre-inducted pBAD_Cas9_sgRNA plasmid CamR+ (BBa_K2457006) AND pRecA plasmid AmpR+ with a linearized Donor DNA (BBa_K2457004) + pKana. We screened over 94 transformants colonies, inoculating in 200µL of LB + 50µg/mL kanamycin + 25µg/mL chloramphenicol + 100µg/mL ampicillin + 0.2% L-Arabinose + 1mM IPTG to activate the expression of RecA AND Cas9. We measured the initial OD (600nm) and initial fluorescence (exc. 340 nm em. 530 nm) on 96-wells plates applying the Hidex Chameleon V spectrofluorimeter. The process was repeated for each hour over 10 hours while the 96-wells plate kept growing on a shaker at 37ºC.

C) carrying a pre-inducted RecA.

We transformed through electroporation E. coli K12 MG1655 carrying a pRecA (AmpR+) with pBAD_Cas9_sgRNA plasmid CamR+ (BBa_K2457006) and a linearized Donor DNA (BBa_K2457004). We screened over 80 transformants colonies, inoculating in 200µL of LB + 25µg/mL chloramphenicol + 100µg/mL ampicillin + 0.2% L-Arabinose + 1mM IPTG to activate the expression of RecA AND Cas9. We measured the initial OD (600nm) and initial fluorescence (exc. 340 nm em. 530 nm) on 96-wells plates applying the Hidex Chameleon V spectrofluorimeter. The process was repeated for each hour over 10 hours while the 96-wells plate kept growing on a shaker at 37ºC.

Figure 6: CRISPeasy-in results.

Leading from the achieved results, it was noted that has certain variations between the methodologies performances: with non-induced Cas9 (30% recombinants), with pre-induced Cas9 and RecA (90% recombinants) and with exclusively pre-induced RecA (95% recombinants).

The non-induced Cas9 method possibly do not have the best performance (30%) due to the absence of Cas9 protein when the Donor DNA is inserted into genome, causing a delay in the target sequence cleavage by Cas9, and, therefore, also the delay in homologous recombination, then the major linear Donor DNA is degraded in the bacterial cytosol.

The pre-induced Cas9 and RecA presented a very good result and similar to the most effective approach. When Donor DNA is inserted into the genome, is already happening the cleavage by Cas9 and RecA is investigating a homologous sequence to the broken strand, then Donor DNA is quickly incorporated, having less DNA degradation.

We found out that the most efficient method was the one which had only RecA pre-induced, since Cas9 presence affects the cells growth, therefore, when Cas9 and Donor DNA are added simultaneously, it will have the normal cell growth, beyond the further homologous recombination.

The CRISPeasy framework development can be a boost for an easily AND reliable way to use bacterial genome editing based on CRISPR/Cas9. We encourage teams to dive into CRISPR's standardization with us and expect to be able to see in the next years more and more projects with technique's improvement!

Sequencing

Figure 7:Sequencing electropherogram from BBa_K2457000.

Figure 8:Alignment of the designed sequence and our final construction from BBa_K2457000.

Sequence and Features